NetScientific PLC NetScientific Capital Markets Day (6699L)
29 Abril 2015 - 5:00AM
UK Regulatory
TIDMNSCI
RNS Number : 6699L
NetScientific PLC
29 April 2015
NetScientific plc
("NetScientific" or the "Group")
Capital Markets Day
London, UK - 29 April 2015 - NetScientific plc (AIM: NSCI), the
biomedical and healthcare technology group, will be holding a
Capital Markets Day on Friday 15 May 2015 at 10.30am - 3.00pm in
London to provide an update on the outcome of its strategy review
and highlight the achievements and progress of its key portfolio
companies.
Sir Richard Sykes will introduce the day and provide a strategy
update, then seven key portfolio companies will present. This will
be followed by an opportunity to network and meet the portfolio
companies on a one to one basis.
Attending portfolio companies include (full details of the
companies are below):
Digital Health
-- Wanda Health
-- Glucosense
-- G-Tech Medical
Diagnostics
-- Vortex BioSciences
-- Glycotest
-- ProAxsis
Therapeutics
-- PDS Biotechnology
Please email netscientific@instinctif.com for more details or to
book a one to one meeting.
-Ends-
About NetScientific
NetScientific is a biomedical and healthcare technology group
that funds and develops technologies that offer transformative
benefits to people's lives and society through improved diagnosis,
prognosis and treatment. For more information, please visit the
website at www.NetScientific.net.
Attending portfolio companies
Digital Health
Wanda Health - Healthcare Analytics
-- Wanda Health is developing cloud-based analytics, as part of
a total patient management solution, in partnership with other
healthcare providers. The core analytics engine is based on 12
years of research at the Wireless Health Institute at UCLA. Wanda
Health completed development of a predictive analytics engine for
use in remotely monitoring patients with Congestive Heart Failure,
the leading cause of hospital re-admissions in USA.
Glucosense - Wearables
-- Glucosense is developing a non-invasive blood glucose sensor,
which has a number of potential professional and consumer
applications. These include as a partial replacement for the
finger-prick testing, continuous non-invasive glucose monitoring
and as a wearable hypoglycaemia-alert device.
G-Tech Medical - Wearables
-- G-Tech Medical is developing a wireless, wearable, disposable
patch, which will help diagnose the root causes of Functional
Gastrointestinal Disorders ('FGIDs'). FGIDs afflict more than 60
million people annually in the US, and are a large burden to the
health care system. The G-Tech patch will measure and characterize
the activity of the main digestive organs under normal daily
conditions to help pinpoint the source of the dysfunction. It will
allow physicians to quickly determine that a functional problem
exists, in many cases allowing them to skip the current invasive,
expensive anatomic testing sequence.
Diagnostics
Vortex Biosciences - Cancer diagnostic
-- Cancer diagnostic instrument company providing liquid biopsy
solutions for isolating, detecting and harvesting circulating
tumour cells ('CTCs') from cancer patients' blood samples. The
company is developing the Vortex VX-1 benchtop instrument, which
runs a simplified, high-speed blood test for a wide range of
metastatic cancers. The instrument harvests live CTCs from patient
blood samples for use in downstream clinical applications such as
monitoring disease progression and drug treatment
effectiveness.
Glycotest - Liver diagnostics
-- Glycotest is developing diagnostic tests designed to support
the accurate diagnosis of liver disease, liver cancers and
fibrosis-cirrhosis, and ultimately help improve disease management
in patients. The technology was spun-out of the Drexel University
College of Medicine and the Baruch S. Blumberg Institute. The first
diagnostic panel under development, measures serum levels of
multiple liver proteins using the company's proprietary technology
to detect early stage Hepatocellular Carcinoma ('HCC'), improving
surveillance of the disease in high-risk populations.
ProAxsis - Respiratory diagnostics
-- The company is developing a range of novel, point of care,
easy to use tests, which will enable routine monitoring and
improved management of patients with chronic conditions, such as
cystic fibrosis and chronic obstructive pulmonary disease. The lead
product, NEATstick(TM) , detects active neutrophil elastase, which
is an early indicator of lung infection in patients with cystic
fibrosis. In parallel with this, ProAxsis is also developing a
range of activity-base immunoassays, which will assist the research
community in the specific measurement of activated protease
disease-biomarkers. Later in 2015, the launch of the first
ProteaseTags(TM) immunoassay tests is anticipated as well as the
completion of pre-clinical development of NEATstick(TM) .
Therapeutics
PDS Biotechnology - Cancer immunotherapy
-- PDS is a clinical stage immunotherapy company developing a
next-generation of simpler, safer and more effective
immunotherapies for cancer and infectious disease. Versamune(R),
its novel synthetic nanoparticle platform technology, activates
multiple immunological mechanisms which direct the targeting of
cancer and infectious disease by the immune system. The company's
lead product, PDS0101, is in phase I clinical trials in the US for
HPV-related cancers. PDS has licensed the Versamune(R) technology
to Merck KGaA for use in two early stage cancer immunotherapy
programmes. The company has also ongoing pre-clinical programmes
for other cancers as well as pandemic influenza.
Contact Details
NetScientific Tel: +44 (0)77 2055 5752
Peter Thoms, CFO
Investec Tel: +44 (0)20 7597 4000
Gary Clarence / Daniel Adams
Instinctif Partners Tel: +44 (0)20 7457 2020
Melanie Toyne-Sewell / Jayne Crook Email: netscientific@instinctif.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCILMRTMBATMMA
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024